Geneos Therapeutics Presents Personalized Neoantigen-Based DNA Therapy That Sustains Anti-tumor Immunity in Brain Cancer Patients and Offers a Path to Dynamic Therapy
PHILADELPHIA, PA, November 16, 2026 / Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-targeted personalized DNA immunotherapy for cancer (PIC), presented follow-up data from extended treatment of two patients with high grade glioma which demonstrates the feasibility of sustained immune surveillance and dynamic therapy in clinical practice. These data were … Read more